Sicart Associates LLC Increases Stock Holdings in Guardant Health, Inc. $GH

Key Points

• Sicart Associates LLC increased its stake in Guardant Health, Inc. by 20.2% during the 2nd quarter, now owning approximately 165,455 shares valued at around $8.61 million, making it the firm's 12th largest holding.
• Guardant Health reported earnings of ($0.44) per share, beating analysts' expectations, with a revenue increase of 31.0% year-over-year for the most recent quarter.
• Multiple research firms have raised their target prices for Guardant Health, with Stifel Nicolaus setting a target at $73.00 and an average consensus rating of "Buy" across the board.

Sicart Associates LLC raised its stake in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 20.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 165,455 shares of the company's stock after purchasing an additional 27,862 shares during the quarter. Guardant Health accounts for 3.0% of Sicart Associates LLC's investment portfolio, making the stock its 12th biggest holding. Sicart Associates LLC owned about 0.13% of Guardant Health worth $8,610,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of GH. GAMMA Investing LLC grew its position in shares of Guardant Health by 11,765.1% in the first quarter. GAMMA Investing LLC now owns 17,679 shares of the company's stock valued at $7,530,000 after purchasing an additional 17,530 shares during the period. Rhumbline Advisers lifted its stake in shares of Guardant Health by 4.9% in the first quarter. Rhumbline Advisers now owns 175,432 shares of the company's stock worth $7,473,000 after acquiring an additional 8,202 shares in the last quarter. MRA Advisory Group acquired a new position in shares of Guardant Health in the first quarter worth about $651,000. Handelsbanken Fonder AB lifted its stake in shares of Guardant Health by 13.1% in the first quarter. Handelsbanken Fonder AB now owns 32,741 shares of the company's stock worth $1,395,000 after acquiring an additional 3,800 shares in the last quarter. Finally, Fifth Third Bancorp acquired a new position in shares of Guardant Health in the first quarter worth about $279,000. 92.60% of the stock is owned by institutional investors and hedge funds.

Guardant Health Stock Up 0.8%

GH opened at $62.48 on Wednesday. The stock has a fifty day moving average of $56.27 and a 200-day moving average of $49.16. The firm has a market capitalization of $7.79 billion, a P/E ratio of -18.65 and a beta of 1.46. Guardant Health, Inc. has a 12-month low of $20.14 and a 12-month high of $68.00.

Guardant Health (NASDAQ:GH - Get Free Report) last released its earnings results on Wednesday, July 30th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.52) by $0.08. The business had revenue of $232.09 million during the quarter, compared to analysts' expectations of $211.19 million. Guardant Health's revenue for the quarter was up 31.0% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.84) EPS. Guardant Health has set its FY 2025 guidance at EPS. On average, analysts expect that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Medina Manuel Hidalgo sold 2,165 shares of the company's stock in a transaction on Friday, September 12th. The shares were sold at an average price of $54.16, for a total value of $117,256.40. Following the transaction, the director directly owned 851 shares of the company's stock, valued at approximately $46,090.16. This represents a 71.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Helmy Eltoukhy sold 300,000 shares of the stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $59.45, for a total transaction of $17,835,000.00. Following the transaction, the chief executive officer directly owned 2,123,499 shares in the company, valued at $126,242,015.55. The trade was a 12.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 302,691 shares of company stock worth $17,981,965 over the last ninety days. 6.10% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research firms have recently commented on GH. Stifel Nicolaus set a $73.00 target price on Guardant Health in a report on Thursday, September 25th. Mizuho upped their target price on Guardant Health from $65.00 to $70.00 and gave the stock an "outperform" rating in a research report on Thursday, September 25th. Leerink Partners upped their target price on Guardant Health from $70.00 to $75.00 and gave the company an "outperform" rating in a report on Thursday, September 25th. Canaccord Genuity Group lifted their price target on Guardant Health from $65.00 to $75.00 and gave the stock a "buy" rating in a research note on Friday, September 26th. Finally, Cowen reissued a "buy" rating on shares of Guardant Health in a research note on Thursday, September 25th. One research analyst has rated the stock with a Strong Buy rating and twenty-two have issued a Buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $65.25.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.